Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma

Bookmark and Share
Published: 15 Jun 2020
Views: 112
Rating:
Save
Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

Prof Davendra Sohal speaks to ecancer about the results of the SWOG S1505 trial that were presented at the ASCO 2020 Virtual Meeting.

The phase II trial used perioperative chemotherapy with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma.

Prof Sohal reports that the results indicate no improvement in overall survival with very similar results in both arms, and he explains some of the important lessons that can be taken from the trial.